MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome

  MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of AS.  Read Press Release  Read […]

2024 Global Science Summit Recap

The 17th Global Science Summit brought together over 1,000 in-person and virtual attendees from 55 countries around the world!

Spreading Awareness on the Airwaves

As part of International Angelman Day, Heather Brady, Louise Prince, and Sarah Washbrook took to the airwaves to raise awareness about Angelman syndrome, the work of FAST UK, and the urgent need for research and support.

Sarah’s TV appearance and BBC Wales article

We’re so proud of Sarah Washbrook, a dedicated mum, advocate, and fundraiser, who is helping to shine a light on Angelman syndrome. She and her son, Ivor, were recently featured in a BBC Wales article about working carers, sharing the realities of life as a parent to a child with Angelman syndrome.